Omega Diagnostics Group PLC
31 August 2007
Omega Diagnostics Group PLC
31 August 2007
Omega Diagnostics Group PLC ('Omega' or 'the Company')
Directors Shareholdings & Issue of Equity
Omega Diagnostics Group PLC announces that following its share consolidation and
capital reorganization (the 'Share Consolidation' and the 'Capital
Reorganisation' respectively), 9,684,470 new Ordinary Shares of 4 pence each ('
New Ordinary Shares') have today been admitted to AIM (the 'First Admission').
Application has been made for a further 5,191,223 New Ordinary Shares to be
admitted to AIM, which is expected to become effective on 3 September 2007 (the
'Second Admission').
As part of the placing related to the acquisitions of Genesis Diagnostics
Limited and Cambridge Nutritional Sciences Limited announced on 6 August 2007
and approved by shareholders at the EGM of the Company yesterday
(the 'Placing'), David Evans, Non-Executive Chairman and Andrew Shepherd,
Chief Executive Officer of the Company have today purchased New Ordinary Shares
at the placing price of 30p per share. The number of New Ordinary Shares
purchased by each Director and their resultant holding of New Ordinary Shares in
the Company is set out below:
No. of New Interest in New Interest in total Interest in total
Ordinary Shares Ordinary Shares issued share issued share
purchased as part following the capital following capital following
of the Placing Placing First Admission Second Admission
David Evans, Non-Executive 100,000 100,000 1.03% 0.67%
Chairman
Andrew Shepherd, Chief 100,000 902,568 9.32% 6.07%
Executive Officer
In addition, in accordance with the details of the Share Consolidation set out
in the Admission Document published on 3 August 2007, David Evans yesterday
purchased 25 non-consolidated Ordinary Shares of 1p each in the Company ('Old
Ordinary Shares') at the price of 1p per Old Ordinary Share, being the par value
of the Old Ordinary Shares. This was in order to increase the issued share
capital of the Company to a number divisible by 40 prior to the Share
Consolidation becoming effective. Following this transaction, David Evans held
less than 0.01% of yesterday's issued share capital.
Following the implementation of the Share Consolidation, these 25 Old Ordinary
Shares are now a fraction of a New Ordinary Share and have been aggregated with
the fractions of New Ordinary Shares to which other fractional shareholders of
the Company are entitled so as to form full New Ordinary Shares and will be sold
in the market for the benefit of the Company. In total there are 19 New
Ordinary Shares resulting from fractional entitlements to New Ordinary Shares.
The issue of 25 Old Ordinary Shares of 1p each to David Evans has resulted in
one additional New Ordinary Share following aggregation with other fractional
entitlements after the Share Consolidation. Application has been made for this
additional New Ordinary Share to be admitted to trading on AIM, which is
expected to become effective on 6 September 2007. Following Admission of this
additional New Ordinary Share the Company's issued share capital will consist of
14,875,694 New Ordinary Shares.
Contacts:
Omega Diagnostics Group PLC
Tel: 01259 763030
Andrew Shepherd, Chief Executive
Kieron Harbinson, Finance Director
www.omegadiagnostics.com
Landsbanki Securities (UK) Limited
Nominated Adviser & Broker
Tel: 020 7426 9000
Thilo Hoffmann/Simon Brown, Corporate Finance
Parkgreen Communications Limited
Ben Knowles
T. 020 7479 7933
Mob. 07900 346 978
Ben.knowles@parkgreenmedia.com
This information is provided by RNS
The company news service from the London Stock Exchange